sotalol has been researched along with Tachyarrhythmia in 121 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of our study was to compare sotalol (S) versus beta-blocking agents (BB) in terms of prevention of ATA, cardioversions (CVs), and cardiovascular hospitalizations (H) in patients paced for bradycardia-tachycardia form of sinus node disease (BT-SND)." | 9.13 | The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. ( Boriani, G; Botto, G; Capucci, A; Favale, S; Marotta, T; Molon, G; Porfilio, A; Proclemer, A; Spampinato, A; Vimercati, M, 2008) |
| "These results show that MgCl(2), in addition to sotalol, is not more effective than sotalol alone in the prevention of tachyarrhythmias after CABG." | 9.11 | Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery. ( Beukema, WP; Geertman, H; Sie, HT; van der Starre, PJ; van Rooyen-Butijn, M, 2004) |
| "We randomized 61 patients with paroxysmal atrial fibrillation (AF) ( < 48 hours from onset) to either sotalol or quinidine treatment." | 9.08 | Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). ( Halinen, MO; Huttunen, M; Paakkinen, S; Tarssanen, L, 1995) |
| "Since in patients with ventricular tachycardia (VT) and compromised left ventricular function, antiarrhythmic therapy poses a particular problem, an open-label safety study of d-sotalol, a new class III antiarrhythmic agent, was performed." | 9.08 | Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction. ( Düren, DR; Koch, KT; van Zwieten, PA, 1995) |
| "Oral sotalol was given to 64 patients (78% postinfarction) with recurrent, reentrant ventricular tachycardia (VT) during an average follow-up period of 19." | 9.06 | Efficacy of oral sotalol in reentrant ventricular tachycardia. ( Haitus, B; Jardine, R; Millar, RN; Obel, IW, 1990) |
| " Its efficacy was tested in 9 patients with sustained ventricular tachycardia (VT) that had previously remained inducible during electrophysiologic testing of type I drugs (procainamide or quinidine)." | 9.06 | Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. ( Constantin, L; Hopson, R; Kienzle, MG; Martins, JB; McCue, ML; Wendt, DJ, 1988) |
| "Thirty-five patients with suspected acute myocardial infarction were studied in a randomised controlled trial to determine whether the catecholamine response to myocardial infarction was altered by administration of the beta blocker, sotalol, given within six hours of the onset of chest pain." | 9.06 | The catecholamine response to acute myocardial infarction: effect of early administration of sotalol. ( Arnolda, L; McGrath, B; Saltups, A, 1986) |
| " Log dose-response curves for increases in both heart rate (mostly beta 1), and amplitude of physiologic tremor (beta 2) were constructed for each subject in the control state and 2 hr after 10 or 40 mg propranolol, 200 mg sotalol, or placebo." | 9.05 | Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor. ( Fish, A; Perucca, E; Pickles, H; Richens, A, 1981) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "Sotalol is a class III antiarrhythmic agent that is highly effective for tachyarrhythmias in adults, but its efficacy in patients with congenital heart disease (CHD) remains unclear." | 7.74 | Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. ( Kamakura, S; Kurosaki, K; Miyazaki, A; Ohuchi, H; Yagihara, T; Yamada, O, 2008) |
| "This was a retrospective study of patients treated for fetal tachycardia with sotalol in a pediatric cardiology department over a ten-year period." | 7.73 | Sotalol in the treatment of fetal tachyarrhythmia. ( Kaku, S; Macedo, AJ; Nogueira, G; Rebelo, M; Trigo, C, 2006) |
| "The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of sotalol in the treatment of fetal tachycardia." | 7.72 | Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003) |
| " Propranolol, dl-sotalol, azimilide, and d-sotalol inhibited isoproterenol-induced tachycardia with IC50 values (the concentration giving 50% inhibition of isoproterenol-stimulated heart rate) of 0." | 7.70 | Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart. ( Brooks, RR; Carpenter, JF; Miller, KE, 1998) |
| "The efficacy of oral sotalol in preventing sustained ventricular tachycardia induction by invasive electrophysiological testing was assessed in 22 patients (60 +/- 9 years) with prior myocardial infarction." | 7.68 | Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. ( Campa, MA; Dubuc, M; Kaltenbrunner, W; Kus, T; Nadeau, R; Shenasa, M, 1992) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 7.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "The safety and efficacy of oral sotalol, an investigational beta-adrenergic blocker with class III antiarrhythmic drug properties, were examined in a multicenter study in 236 patients with sustained ventricular tachyarrhythmias." | 7.68 | Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. ( Dunnington, CS; Kehoe, RF; Mattioni, TA; Spangenberg, RB; Yu, G; Zheutlin, TA, 1990) |
| "Thirteen patients developed syncope and a prolonged QTc interval while taking therapeutic doses of sotalol." | 7.67 | Sotalol, hypokalaemia, syncope, and torsade de pointes. ( Barlow, JB; McKibbin, JK; Millar, RN; Obel, IW; Pocock, WA, 1984) |
| "Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studies to establish the therapeutic efficacy of sotalol." | 7.67 | Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. ( Brachmann, J; Cobbe, S; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1984) |
| "The efficacy and safety of sotalol were assessed by electrophysiologic testing and ambulatory recordings in 16 patients with recurrent sustained ventricular tachycardia (VT) or nonfatal cardiac arrest who were refractory to an average of 4." | 7.67 | Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. ( Chen, YW; Cohen, A; Fletcher, RD; Gottdiener, J; Peralba, J; Singh, SN; Thoben-O'Grady, L; Wish, M, 1988) |
| "The effects of oral sotalol were compared with 1000 and 1500 mg of procainamide in 23 patients with sustained ventricular tachycardia." | 7.67 | A comparison of sotalol and procainamide in symptomatic ventricular tachycardia. ( Clement, DL; Colardyn, F; Jordaens, LJ, 1989) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 7.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 7.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "A case of QT prolongation and ventricular tachyarrhythmia in a 57-year-old patient treated with small therapeutic doses of sotalol is reported." | 7.67 | [Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?]. ( Ophoff, N; Toker, Y, 1988) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 7.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| "Programmed ventricular stimulation and ambulatory electrocardiography were performed both before and during oral sotalol therapy in 39 patients with ventricular tachyarrhythmia inducible by programmed stimulation (sustained ventricular tachycardia [n = 31], ventricular fibrillation [n = 3], nonsustained ventricular tachycardia [n = 5])." | 7.67 | Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. ( Bach, P; Haberl, R; Steinbeck, G, 1986) |
| "The electrophysiologic effects of sotalol were studied in 11 patients with Wolff-Parkinson-White syndrome and 9 patients with AV nodal reentrant tachycardia." | 7.67 | [Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia]. ( Kuhl, AJ; Lüderitz, B; Manz, M, 1985) |
| " Its short-term antiarrhythmic effects were compared with those of metoprolol, which has neither short-term class III nor membrane-stabilizing action, on reentrant ventricular arrhythmias produced by programmed stimulation in 17 conscious dogs 3 to 8 days after myocardial infarction." | 7.66 | Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. ( Brachmann, J; Cobbe, SM; Hoffman, E; Kübler, W; Ritzenhoff, A; Senges, J, 1983) |
| " Three of four patients received lidocaine, but with no effect on multiple ventricular premature beats (VPB) or ventricular tachycardia (VT) of "torsade de pointes"-type." | 7.66 | Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes). ( Pellinen, T; Tötterman, KJ; Turto, H, 1982) |
| "Sotalol was partially effective for AVRT, however, it did not prevent AF, RF ablation cured all arrythmias." | 5.35 | [Sotalol prevents atrio-ventricular tachycardia but not atrial fibrillation with rapid ventricular response in a patient wiht WPW syndrome]. ( Bodalski, R; Orczykowski, M; Szufladowicz, E; Szumowski, L; Walczak, F; Zakrzewska-Koperska, J, 2008) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 5.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "The individual bioavailability of enterally administered drugs is usually uncertain in case of reduced bowel length." | 5.30 | [Bioavailability of sotalol in short bowel syndrome]. ( Bach, F; Claus, T; Juckenhöfel, S; Molter, G; Silomon, M, 1999) |
| "Sotalol is a beta-blocking agent endowed with class III electrophysiological properties." | 5.27 | [Sotalol-induced torsades de pointe in the conscious dog with atrioventricular block. Role of hypokalemia]. ( Cheymol, G; Chezalviel, F; Davy, JM; Ertzbischoff, O; Lainée, P; Motte, G; Poirier, JM; Weissenburger, J, 1988) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 5.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| "Sotalol is a unique beta-blocker that lengthens cardiac repolarization and effective refractory period (ERP)." | 5.27 | Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Feld, G; Hendrickson, J; Nademanee, K; Singh, BN; Singh, PN, 1985) |
| "Sotalol was administered intravenously (n = 16) in a dose of 1." | 5.27 | [Electrophysiologic effect of sotalol in supraventricular tachycardias]. ( Borggrefe, M; Breithardt, G, 1985) |
| "Severe ventricular tachyarrhythmias occurred in five of the six patients, the risk was greatest up to 20 h after the ingestion of sotalol." | 5.26 | Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. ( Elonen, E; Laakso, M; Neuvonen, PJ; Vuorenmaa, T, 1981) |
| " The aim of our study was to compare sotalol (S) versus beta-blocking agents (BB) in terms of prevention of ATA, cardioversions (CVs), and cardiovascular hospitalizations (H) in patients paced for bradycardia-tachycardia form of sinus node disease (BT-SND)." | 5.13 | The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. ( Boriani, G; Botto, G; Capucci, A; Favale, S; Marotta, T; Molon, G; Porfilio, A; Proclemer, A; Spampinato, A; Vimercati, M, 2008) |
| "These results show that MgCl(2), in addition to sotalol, is not more effective than sotalol alone in the prevention of tachyarrhythmias after CABG." | 5.11 | Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery. ( Beukema, WP; Geertman, H; Sie, HT; van der Starre, PJ; van Rooyen-Butijn, M, 2004) |
| "We randomized 61 patients with paroxysmal atrial fibrillation (AF) ( < 48 hours from onset) to either sotalol or quinidine treatment." | 5.08 | Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). ( Halinen, MO; Huttunen, M; Paakkinen, S; Tarssanen, L, 1995) |
| "Since in patients with ventricular tachycardia (VT) and compromised left ventricular function, antiarrhythmic therapy poses a particular problem, an open-label safety study of d-sotalol, a new class III antiarrhythmic agent, was performed." | 5.08 | Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction. ( Düren, DR; Koch, KT; van Zwieten, PA, 1995) |
| "The relative safety and efficacy of intravenous administration of adenosine, lignocaine, disopyramide, flecainide, and sotalol for termination of stable, induced ventricular tachycardia was assessed in serial trials." | 5.06 | Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. ( Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990) |
| "Oral sotalol was given to 64 patients (78% postinfarction) with recurrent, reentrant ventricular tachycardia (VT) during an average follow-up period of 19." | 5.06 | Efficacy of oral sotalol in reentrant ventricular tachycardia. ( Haitus, B; Jardine, R; Millar, RN; Obel, IW, 1990) |
| " Its efficacy was tested in 9 patients with sustained ventricular tachycardia (VT) that had previously remained inducible during electrophysiologic testing of type I drugs (procainamide or quinidine)." | 5.06 | Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. ( Constantin, L; Hopson, R; Kienzle, MG; Martins, JB; McCue, ML; Wendt, DJ, 1988) |
| "Thirty-five patients with suspected acute myocardial infarction were studied in a randomised controlled trial to determine whether the catecholamine response to myocardial infarction was altered by administration of the beta blocker, sotalol, given within six hours of the onset of chest pain." | 5.06 | The catecholamine response to acute myocardial infarction: effect of early administration of sotalol. ( Arnolda, L; McGrath, B; Saltups, A, 1986) |
| " Log dose-response curves for increases in both heart rate (mostly beta 1), and amplitude of physiologic tremor (beta 2) were constructed for each subject in the control state and 2 hr after 10 or 40 mg propranolol, 200 mg sotalol, or placebo." | 5.05 | Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor. ( Fish, A; Perucca, E; Pickles, H; Richens, A, 1981) |
| "We performed a systematic review and meta-analysis to compare digoxin, flecainide, or sotalol as first-line therapy for fetal tachycardia." | 4.95 | Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. ( Frommelt, MA; Hill, GD; Kovach, JR; Saudek, DE; Singh, AK; Wehrheim, K, 2017) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "A case is described of cardiogenic shock that occurred following use of sotalol in a patient with severe left ventricular dysfunction." | 3.81 | Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy. ( Bergin, P; Kaye, DM; Mariani, JA; McGiffin, DC; Saxena, P; Stokes, MB, 2015) |
| "Sotalol is a class III antiarrhythmic agent that is highly effective for tachyarrhythmias in adults, but its efficacy in patients with congenital heart disease (CHD) remains unclear." | 3.74 | Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. ( Kamakura, S; Kurosaki, K; Miyazaki, A; Ohuchi, H; Yagihara, T; Yamada, O, 2008) |
| "This was a retrospective study of patients treated for fetal tachycardia with sotalol in a pediatric cardiology department over a ten-year period." | 3.73 | Sotalol in the treatment of fetal tachyarrhythmia. ( Kaku, S; Macedo, AJ; Nogueira, G; Rebelo, M; Trigo, C, 2006) |
| "The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of sotalol in the treatment of fetal tachycardia." | 3.72 | Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003) |
| "7 mM and Mg2+=1 mM), d,l-sotalol (10 and 30 microM), a class III antiarrhythmic drug, prolonged ventricular repolarization, such as QT intervals and monophasic action potential duration, and induced early after-depolarization and polymorphic ventricular tachyarrhythmia." | 3.71 | Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block. ( Ito, T; Kii, Y, 2002) |
| " Propranolol, dl-sotalol, azimilide, and d-sotalol inhibited isoproterenol-induced tachycardia with IC50 values (the concentration giving 50% inhibition of isoproterenol-stimulated heart rate) of 0." | 3.70 | Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart. ( Brooks, RR; Carpenter, JF; Miller, KE, 1998) |
| "d-1 sotalol is one of the most effective antiarrhythmic agents currently available for ventricular tachyarrhythmias, but the recommended infusion rate of 10-20 min is too slow for rapid pharmacological termination of sustained ventricular tachycardia (VT) or for use during cardiac arrest." | 3.69 | Rapid intravenous infusion of d-1 sotalol: time to onset of effects on ventricular refractoriness, and safety. ( Cooper, MJ; Ho, DS; Richards, DA; Ross, DL; Uther, JB; Zecchin, RP, 1995) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "Intravenous amiodarone is an effective treatment for supraventricular and ventricular tachyarrhythmias." | 3.69 | Acute pulmonary toxicity in an infant from intravenous amiodarone. ( Daniels, CJ; Franklin, WH; Hammond, S; Schutte, DA, 1997) |
| " In patients refractory to amiodarone alone or to a combination with mexiletine, the combined treatment with amiodarone and class-I-C drugs such as flecainide and encainide prolongs the cycle length of ventricular tachycardia, but does not suppress induction of ventricular tachycardia during programmed stimulation." | 3.68 | [Combination anti-arrhythmic drug therapy]. ( Jung, W; Lüderitz, B; Manz, M, 1992) |
| "The efficacy of oral sotalol in preventing sustained ventricular tachycardia induction by invasive electrophysiological testing was assessed in 22 patients (60 +/- 9 years) with prior myocardial infarction." | 3.68 | Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. ( Campa, MA; Dubuc, M; Kaltenbrunner, W; Kus, T; Nadeau, R; Shenasa, M, 1992) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 3.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "The safety and efficacy of oral sotalol, an investigational beta-adrenergic blocker with class III antiarrhythmic drug properties, were examined in a multicenter study in 236 patients with sustained ventricular tachyarrhythmias." | 3.68 | Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. ( Dunnington, CS; Kehoe, RF; Mattioni, TA; Spangenberg, RB; Yu, G; Zheutlin, TA, 1990) |
| "Thirteen patients developed syncope and a prolonged QTc interval while taking therapeutic doses of sotalol." | 3.67 | Sotalol, hypokalaemia, syncope, and torsade de pointes. ( Barlow, JB; McKibbin, JK; Millar, RN; Obel, IW; Pocock, WA, 1984) |
| "Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studies to establish the therapeutic efficacy of sotalol." | 3.67 | Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. ( Brachmann, J; Cobbe, S; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1984) |
| "A case of sotalol-induced polymorphous ventricular tachycardia (torsade de pointes) is presented." | 3.67 | Sotalol-induced torsade de pointes. ( Brucan, A; Cercek, B; Horvat, M; Rakovec, P; Rode, P, 1984) |
| "The efficacy and safety of sotalol were assessed by electrophysiologic testing and ambulatory recordings in 16 patients with recurrent sustained ventricular tachycardia (VT) or nonfatal cardiac arrest who were refractory to an average of 4." | 3.67 | Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. ( Chen, YW; Cohen, A; Fletcher, RD; Gottdiener, J; Peralba, J; Singh, SN; Thoben-O'Grady, L; Wish, M, 1988) |
| "The effects of oral sotalol were compared with 1000 and 1500 mg of procainamide in 23 patients with sustained ventricular tachycardia." | 3.67 | A comparison of sotalol and procainamide in symptomatic ventricular tachycardia. ( Clement, DL; Colardyn, F; Jordaens, LJ, 1989) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 3.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 3.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "5 V, 750 ms) or programmed ventricular stimulation, creation of a small myocardial infarction, and application of antiarrhythmic drugs (ajmalin, lidocaine, sotalol)." | 3.67 | Acute induction of sustained ventricular tachycardia: a new porcine model. ( Lüderitz, B; Nitsch, J; Schmid, C, 1989) |
| "A case of QT prolongation and ventricular tachyarrhythmia in a 57-year-old patient treated with small therapeutic doses of sotalol is reported." | 3.67 | [Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?]. ( Ophoff, N; Toker, Y, 1988) |
| "The authors report two cases of fetal tachycardia treated in utero by digitalis (Digoxin) and a beta-blocker (Sotalol)." | 3.67 | [In utero treatment of fetal tachycardias with a digitalis-beta blocker combination. Apropos of 2 cases]. ( Auzelle, MP; Badoual, J; Boccara, JF; Caldera, R; Chavinie, J; Lachassine, E; Mensire, A, 1987) |
| "A young woman had been on antiarrhythmic treatment with sotalol 80-160 mg daily for three years because of ventricular tachycardia." | 3.67 | Clinical course, serum concentrations and elimination rate in a case of massive sotalol intoxication. ( Edvardsson, N; Varnauskas, E, 1987) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 3.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| "Programmed ventricular stimulation and ambulatory electrocardiography were performed both before and during oral sotalol therapy in 39 patients with ventricular tachyarrhythmia inducible by programmed stimulation (sustained ventricular tachycardia [n = 31], ventricular fibrillation [n = 3], nonsustained ventricular tachycardia [n = 5])." | 3.67 | Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. ( Bach, P; Haberl, R; Steinbeck, G, 1986) |
| "Eighteen patients with sustained ventricular tachycardia underwent serial electrophysiological studies to establish the therapeutic efficacy of sotalol as compared to other available anti-arrhythmic agents." | 3.67 | Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol. ( Brachmann, J; Cobbe, SM; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1985) |
| "The electrophysiologic effects of sotalol were studied in 11 patients with Wolff-Parkinson-White syndrome and 9 patients with AV nodal reentrant tachycardia." | 3.67 | [Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia]. ( Kuhl, AJ; Lüderitz, B; Manz, M, 1985) |
| " Its short-term antiarrhythmic effects were compared with those of metoprolol, which has neither short-term class III nor membrane-stabilizing action, on reentrant ventricular arrhythmias produced by programmed stimulation in 17 conscious dogs 3 to 8 days after myocardial infarction." | 3.66 | Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. ( Brachmann, J; Cobbe, SM; Hoffman, E; Kübler, W; Ritzenhoff, A; Senges, J, 1983) |
| " Three of four patients received lidocaine, but with no effect on multiple ventricular premature beats (VPB) or ventricular tachycardia (VT) of "torsade de pointes"-type." | 3.66 | Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes). ( Pellinen, T; Tötterman, KJ; Turto, H, 1982) |
| "Standardized treatment of fetal tachyarrhythmia has not been established." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy." | 2.82 | Arrhythmias in Pregnancy. ( Briller, JE; Elkayam, U; Lakkireddy, DR; Mason, PK; Merchant, FM; Patel, H; Pillarisetti, J; Russo, AM; Tamirisa, KP; Vaseghi, M; Volgman, AS, 2022) |
| "Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed." | 2.69 | Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. ( Henry, PD; Hohnloser, SH; Pacifico, A; Prystowsky, EN; Saksena, S; Tao, B; Williams, JH, 1999) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| "Atrial fibrillation is the most common arrhythmia encountered postoperatively, although ventricular arrhythmias and conduction disturbances can also occur." | 2.41 | Cardiac surgery: postoperative arrhythmias. ( Chung, MK, 2000) |
| "The pharmacological treatment of fetal tachycardia (FT) has been described in various publications." | 2.41 | Drug treatment of fetal tachycardias. ( Ambachtsheer, BE; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, TF; Visser, GH, 2002) |
| "Torsades de pointes arrhythmia is an undesirable side-effect closely coupled to specific class-III action that may limit their future use." | 2.38 | [New anti-arrhythmia agents]. ( Honerjäger, P; Schmidt, G, 1992) |
| "Time to persistent arrhythmia recurrence was compared between first and multiple DCCV, and the effect of age, gender, presence of heart disease, left atrial size, fractional shortening, arrhythmia duration, anti-arrhythmic drug therapy (AAD) and other concomitant cardiac medication was evaluated using the Kaplan-Meier method and Cox's Proportional-hazards model." | 1.36 | First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes. ( Arya, A; Boodhoo, L; Bordoli, G; Cheek, E; Large, J; Lloyd, GW; Mitchell, A; Patel, NR; Pugh, P; Silberbauer, JS; Sulke, AN; Taggu, W; Vrahimides, J, 2010) |
| "Sotalol was partially effective for AVRT, however, it did not prevent AF, RF ablation cured all arrythmias." | 1.35 | [Sotalol prevents atrio-ventricular tachycardia but not atrial fibrillation with rapid ventricular response in a patient wiht WPW syndrome]. ( Bodalski, R; Orczykowski, M; Szufladowicz, E; Szumowski, L; Walczak, F; Zakrzewska-Koperska, J, 2008) |
| "Two patients presented with ventricular tachycardia and one had an atrioventricular re-entrant tachycardia." | 1.33 | Tachycardia-induced elevations in cardiac troponin in the absence of coronary artery disease. ( Cruz, L; Hong, R; Yeo, KK, 2006) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | 1.31 | [Ion channels and arrhythmias]. ( Borchard, U; Hafner, D, 2000) |
| "Atrial tachyarrhythmias were induced by right atrial burst pacing." | 1.30 | Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system. ( Fries, R; Heisel, A; Jung, J; Ozbek, C; Schieffer, H; Sen, S; Stopp, M, 1997) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 1.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "The individual bioavailability of enterally administered drugs is usually uncertain in case of reduced bowel length." | 1.30 | [Bioavailability of sotalol in short bowel syndrome]. ( Bach, F; Claus, T; Juckenhöfel, S; Molter, G; Silomon, M, 1999) |
| "Sotalol is a beta blocker with class III activity." | 1.28 | Effectiveness of oral sotalol for treatment of pediatric arrhythmias. ( Fournier, A; Maragnès, P; Tipple, M, 1992) |
| "A patient with preexistent left bundle branch block and spontaneous ventricular tachycardia based upon the bundle branch reentry mechanism underwent electrophysiological testing for the evaluation of sotalol drug efficacy." | 1.28 | Inadvertent catheter-induced right bundle branch block in a patient with preexistent left bundle branch block and recurrent macroreentrant ventricular tachycardia. ( Gössinger, HD; Leitha, T; Mösslacher, H; Siostrzonek, P; Wagner, L, 1989) |
| "Sotalol is a beta-blocking agent endowed with class III electrophysiological properties." | 1.27 | [Sotalol-induced torsades de pointe in the conscious dog with atrioventricular block. Role of hypokalemia]. ( Cheymol, G; Chezalviel, F; Davy, JM; Ertzbischoff, O; Lainée, P; Motte, G; Poirier, JM; Weissenburger, J, 1988) |
| "Sotalol was found to be effective therapy for a subset of patients with ventricular tachycardia unresponsive to type IA drugs." | 1.27 | Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. ( Gonzalez, R; Griffin, JC; Herre, JM; Sauve, MJ; Scheinman, MM; Sharkey, H, 1988) |
| "D-sotalol appears to be an effective antiarrhythmic drugs and appears to be well tolerated." | 1.27 | The antiarrhythmic effects of d-sotalol. ( Crocker, K; Schwartz, J; Somberg, JC; Wynn, J, 1987) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 1.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| "Sotalol is a unique beta-blocker that lengthens cardiac repolarization and effective refractory period (ERP)." | 1.27 | Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Feld, G; Hendrickson, J; Nademanee, K; Singh, BN; Singh, PN, 1985) |
| "Sotalol was administered intravenously (n = 16) in a dose of 1." | 1.27 | [Electrophysiologic effect of sotalol in supraventricular tachycardias]. ( Borggrefe, M; Breithardt, G, 1985) |
| "Severe ventricular tachyarrhythmias occurred in five of the six patients, the risk was greatest up to 20 h after the ingestion of sotalol." | 1.26 | Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. ( Elonen, E; Laakso, M; Neuvonen, PJ; Vuorenmaa, T, 1981) |
| "oxprenolol was significantly less at 1 and 2 h and significantly greater at 24 h than after conventional oxprenolol, there was little difference between the effects of the two drugs on an exercise tachycardia." | 1.26 | Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. ( Leahey, WJ; Neill, JD; Shanks, RG; Varma, MP, 1980) |
| "Experimental induction of pulmonary emphysema caused an increase in sensitivity of the rat to toxicity from inhalation of propellants." | 1.25 | Toxicity of aerosol propellants in the respiratory and circulatory systems. VII. Influence of pulmonary emphysema and anesthesia in the rat. ( Aviado, DM; Watanabe, T, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 62 (51.24) | 18.7374 |
| 1990's | 31 (25.62) | 18.2507 |
| 2000's | 16 (13.22) | 29.6817 |
| 2010's | 10 (8.26) | 24.3611 |
| 2020's | 2 (1.65) | 2.80 |
| Authors | Studies |
|---|---|
| Lis, R | 1 |
| Davey, DD | 1 |
| Morgan, TK | 1 |
| Lumma, WC | 1 |
| Wohl, RA | 1 |
| Jain, VK | 1 |
| Wan, CN | 1 |
| Argentieri, TM | 1 |
| Sullivan, ME | 1 |
| Cantor, EH | 1 |
| Tamirisa, KP | 1 |
| Elkayam, U | 1 |
| Briller, JE | 1 |
| Mason, PK | 1 |
| Pillarisetti, J | 1 |
| Merchant, FM | 1 |
| Patel, H | 1 |
| Lakkireddy, DR | 1 |
| Russo, AM | 1 |
| Volgman, AS | 1 |
| Vaseghi, M | 1 |
| Miyoshi, T | 1 |
| Maeno, Y | 1 |
| Hamasaki, T | 1 |
| Inamura, N | 1 |
| Yasukochi, S | 1 |
| Kawataki, M | 1 |
| Horigome, H | 1 |
| Yoda, H | 1 |
| Taketazu, M | 1 |
| Nii, M | 1 |
| Hagiwara, A | 1 |
| Kato, H | 1 |
| Shimizu, W | 1 |
| Shiraishi, I | 1 |
| Sakaguchi, H | 1 |
| Ueda, K | 1 |
| Katsuragi, S | 1 |
| Yamamoto, H | 1 |
| Sago, H | 1 |
| Ikeda, T | 1 |
| Sonesson, SE | 1 |
| Acharya, G | 1 |
| Chatterjee, D | 1 |
| Pasierb, MM | 1 |
| Seslar, SP | 1 |
| Hill, GD | 1 |
| Kovach, JR | 1 |
| Saudek, DE | 1 |
| Singh, AK | 1 |
| Wehrheim, K | 1 |
| Frommelt, MA | 1 |
| Sakurai, K | 1 |
| Takahashi, K | 1 |
| Nakayashiro, M | 1 |
| Borchetta, K | 1 |
| Stokes, MB | 1 |
| Saxena, P | 1 |
| Mariani, JA | 1 |
| Kaye, DM | 1 |
| Bergin, P | 1 |
| McGiffin, DC | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Cuneo, BF | 1 |
| Capucci, A | 1 |
| Botto, G | 1 |
| Molon, G | 1 |
| Spampinato, A | 1 |
| Favale, S | 1 |
| Proclemer, A | 2 |
| Porfilio, A | 1 |
| Marotta, T | 1 |
| Vimercati, M | 1 |
| Boriani, G | 1 |
| Orczykowski, M | 1 |
| Szumowski, L | 1 |
| Szufladowicz, E | 1 |
| Bodalski, R | 1 |
| Zakrzewska-Koperska, J | 1 |
| Walczak, F | 1 |
| Miyazaki, A | 1 |
| Ohuchi, H | 1 |
| Kurosaki, K | 1 |
| Kamakura, S | 1 |
| Yagihara, T | 1 |
| Yamada, O | 1 |
| Arya, A | 1 |
| Silberbauer, JS | 1 |
| Vrahimides, J | 1 |
| Cheek, E | 1 |
| Mitchell, A | 1 |
| Boodhoo, L | 1 |
| Pugh, P | 1 |
| Large, J | 1 |
| Bordoli, G | 1 |
| Taggu, W | 1 |
| Lloyd, GW | 1 |
| Patel, NR | 1 |
| Sulke, AN | 1 |
| Hariman, RJ | 1 |
| Khin, MM | 1 |
| Zoble, RG | 1 |
| Wolbrette, DL | 1 |
| Oudijk, MA | 2 |
| Ruskamp, JM | 2 |
| Ververs, FF | 1 |
| Ambachtsheer, EB | 1 |
| Stoutenbeek, P | 2 |
| Visser, GH | 2 |
| Meijboom, EJ | 2 |
| Trappe, HJ | 3 |
| Brandts, B | 1 |
| Weismueller, P | 1 |
| Geertman, H | 1 |
| van der Starre, PJ | 1 |
| Sie, HT | 1 |
| Beukema, WP | 1 |
| van Rooyen-Butijn, M | 1 |
| Patten, M | 1 |
| Maas, R | 1 |
| Bauer, P | 1 |
| Lüderitz, B | 4 |
| Sonntag, F | 1 |
| Dluzniewski, M | 1 |
| Hatala, R | 1 |
| Opolski, G | 1 |
| Müller, HW | 1 |
| Meinertz, T | 2 |
| Yeo, KK | 1 |
| Cruz, L | 1 |
| Hong, R | 1 |
| Rebelo, M | 1 |
| Macedo, AJ | 1 |
| Nogueira, G | 1 |
| Trigo, C | 1 |
| Kaku, S | 1 |
| Cherpanath, TG | 1 |
| Geisler, FE | 1 |
| van der Meer, BJ | 1 |
| van Veer, NE | 1 |
| Alings, AM | 1 |
| Pickles, H | 1 |
| Perucca, E | 1 |
| Fish, A | 1 |
| Richens, A | 1 |
| Pellinen, T | 2 |
| Tötterman, K | 1 |
| Turto, H | 2 |
| Laakso, M | 2 |
| Pentikäinen, PJ | 1 |
| Pyörälä, K | 1 |
| Neuvonen, PJ | 3 |
| Inama, G | 1 |
| Guareneiro, M | 1 |
| Disertori, M | 1 |
| Camin, G | 1 |
| Fiorentini, F | 1 |
| Nicasi, L | 1 |
| Furlanello, F | 2 |
| McKibbin, JK | 1 |
| Pocock, WA | 1 |
| Barlow, JB | 1 |
| Millar, RN | 2 |
| Obel, IW | 2 |
| Antonaccio, MJ | 1 |
| Lessem, JN | 1 |
| Soyka, LF | 1 |
| Beattie, JM | 1 |
| Cobbe, SM | 2 |
| Hoffman, E | 1 |
| Ritzenhoff, A | 1 |
| Brachmann, J | 5 |
| Kübler, W | 5 |
| Senges, J | 3 |
| Allberry, RA | 1 |
| Kuck, KH | 1 |
| Kunze, KP | 1 |
| Roewer, N | 1 |
| Bleifeld, W | 1 |
| Lengfelder, W | 2 |
| Jauernig, R | 2 |
| Czygan, E | 2 |
| Rizos, I | 2 |
| Cobbe, S | 1 |
| Rakovec, P | 1 |
| Cercek, B | 1 |
| Rode, P | 1 |
| Brucan, A | 1 |
| Horvat, M | 1 |
| Tötterman, KJ | 1 |
| Desoutter, P | 1 |
| Medioni, J | 1 |
| Lerasle, S | 1 |
| Haiat, R | 1 |
| Elonen, E | 2 |
| Vuorenmaa, T | 1 |
| Kontopoulos, A | 1 |
| Filindris, A | 1 |
| Manoudis, F | 1 |
| Metaxas, P | 1 |
| Leahey, WJ | 1 |
| Neill, JD | 1 |
| Varma, MP | 1 |
| Shanks, RG | 1 |
| Halinen, MO | 1 |
| Huttunen, M | 1 |
| Paakkinen, S | 1 |
| Tarssanen, L | 2 |
| Ho, DS | 1 |
| Zecchin, RP | 1 |
| Cooper, MJ | 1 |
| Richards, DA | 1 |
| Uther, JB | 2 |
| Ross, DL | 2 |
| Hohnloser, SH | 2 |
| Faber, TS | 1 |
| Zehender, M | 2 |
| Van de Loo, A | 1 |
| Hohnloser, S | 2 |
| Just, H | 2 |
| Koch, KT | 1 |
| Düren, DR | 1 |
| van Zwieten, PA | 1 |
| Kovoor, P | 1 |
| Byth, K | 1 |
| Böcker, D | 1 |
| Block, M | 1 |
| Borggrefe, M | 3 |
| Breithardt, G | 3 |
| Heisel, A | 1 |
| Jung, J | 1 |
| Fries, R | 1 |
| Stopp, M | 1 |
| Sen, S | 1 |
| Schieffer, H | 1 |
| Ozbek, C | 1 |
| Beaufort-Krol, GC | 1 |
| Bink-Boelkens, MT | 1 |
| Daniels, CJ | 1 |
| Schutte, DA | 1 |
| Hammond, S | 1 |
| Franklin, WH | 1 |
| Miller, KE | 1 |
| Carpenter, JF | 1 |
| Brooks, RR | 1 |
| Pacifico, A | 1 |
| Williams, JH | 1 |
| Tao, B | 1 |
| Saksena, S | 1 |
| Henry, PD | 1 |
| Prystowsky, EN | 1 |
| Podrid, PJ | 1 |
| Silomon, M | 1 |
| Bach, F | 1 |
| Juckenhöfel, S | 1 |
| Claus, T | 1 |
| Molter, G | 1 |
| Borchard, U | 1 |
| Hafner, D | 1 |
| Chung, MK | 1 |
| Ambachtsheer, BE | 1 |
| Ververs, TF | 1 |
| Kii, Y | 1 |
| Ito, T | 1 |
| Watanabe, T | 1 |
| Aviado, DM | 1 |
| Kala, R | 1 |
| Haverkamp, W | 1 |
| Shenasa, M | 2 |
| Hindricks, G | 1 |
| Beyer, T | 2 |
| Schmitt, C | 2 |
| Schöls, W | 2 |
| Montero, M | 1 |
| Hilbel, T | 1 |
| Schweizer, M | 1 |
| Jung, W | 1 |
| Manz, M | 2 |
| Honerjäger, P | 1 |
| Schmidt, G | 1 |
| Hill, BC | 2 |
| Summers, RA | 1 |
| Courtney, KR | 2 |
| Maragnès, P | 1 |
| Tipple, M | 1 |
| Fournier, A | 1 |
| Wagner, X | 1 |
| Jouglard, J | 1 |
| Moulin, M | 1 |
| Miller, AM | 1 |
| Petitjean, J | 1 |
| Pisapia, A | 1 |
| Hunt, AJ | 1 |
| Kus, T | 1 |
| Campa, MA | 1 |
| Nadeau, R | 1 |
| Dubuc, M | 1 |
| Kaltenbrunner, W | 1 |
| Brown, DC | 1 |
| Godman, MJ | 1 |
| Griffith, MJ | 1 |
| Linker, NJ | 1 |
| Garratt, CJ | 1 |
| Ward, DE | 1 |
| Camm, AJ | 1 |
| Dal Forno, P | 1 |
| Cozzi, F | 1 |
| Bettini, R | 1 |
| Jardine, R | 1 |
| Haitus, B | 1 |
| Klein, H | 2 |
| Lichtlen, P | 1 |
| Kehoe, RF | 1 |
| Zheutlin, TA | 1 |
| Dunnington, CS | 1 |
| Mattioni, TA | 1 |
| Yu, G | 1 |
| Spangenberg, RB | 1 |
| Geibel, A | 1 |
| Brugada, P | 2 |
| Waldecker, B | 1 |
| Nademanee, K | 2 |
| Singh, BN | 2 |
| Stroobandt, R | 1 |
| Holvoet, G | 1 |
| Verbeke, N | 1 |
| Kesteloot, H | 1 |
| Singh, SN | 1 |
| Cohen, A | 1 |
| Chen, YW | 1 |
| Wish, M | 1 |
| Thoben-O'Grady, L | 1 |
| Peralba, J | 1 |
| Gottdiener, J | 1 |
| Fletcher, RD | 1 |
| Ciani, R | 1 |
| Feruglio, GA | 1 |
| Gössinger, HD | 2 |
| Siostrzonek, P | 2 |
| Wagner, L | 1 |
| Leitha, T | 1 |
| Mösslacher, H | 2 |
| Jordaens, LJ | 2 |
| Colardyn, F | 1 |
| Clement, DL | 2 |
| Roden, DM | 2 |
| Woosley, RL | 2 |
| Palmer, A | 1 |
| Kuchar, DL | 1 |
| Garan, H | 1 |
| Venditti, FJ | 1 |
| Finkelstein, D | 1 |
| Rottman, JN | 1 |
| McComb, J | 1 |
| McGovern, BA | 1 |
| Ruskin, JN | 1 |
| Schmid, C | 1 |
| Nitsch, J | 1 |
| Janssen, J | 1 |
| Loomans, L | 1 |
| Harink, J | 1 |
| Taams, M | 1 |
| Brunninkhuis, L | 1 |
| van der Starre, P | 1 |
| Kootstra, G | 1 |
| Kienzle, MG | 1 |
| Martins, JB | 1 |
| Wendt, DJ | 1 |
| Constantin, L | 1 |
| Hopson, R | 1 |
| McCue, ML | 1 |
| Davy, JM | 1 |
| Weissenburger, J | 1 |
| Ertzbischoff, O | 1 |
| Lainée, P | 1 |
| Chezalviel, F | 1 |
| Poirier, JM | 1 |
| Cheymol, G | 1 |
| Motte, G | 1 |
| Gonzalez, R | 1 |
| Scheinman, MM | 1 |
| Herre, JM | 1 |
| Griffin, JC | 1 |
| Sauve, MJ | 1 |
| Sharkey, H | 1 |
| Ophoff, N | 1 |
| Toker, Y | 1 |
| Kopelman, HA | 1 |
| Lee, JT | 1 |
| Echt, DS | 1 |
| Schmoliner, R | 1 |
| Grimm, G | 1 |
| Jäger, U | 1 |
| McGrath, B | 1 |
| Arnolda, L | 1 |
| Saltups, A | 1 |
| Auzelle, MP | 1 |
| Mensire, A | 1 |
| Lachassine, E | 1 |
| Caldera, R | 1 |
| Boccara, JF | 1 |
| Chavinie, J | 1 |
| Badoual, J | 1 |
| Llewellyn, MJ | 1 |
| Ramsdale, DR | 1 |
| Edvardsson, N | 1 |
| Varnauskas, E | 1 |
| Schwartz, J | 1 |
| Crocker, K | 1 |
| Wynn, J | 1 |
| Somberg, JC | 1 |
| Lichtlen, PR | 1 |
| Opie, LH | 1 |
| Steinbeck, G | 1 |
| Bach, P | 1 |
| Haberl, R | 1 |
| Rudnicki, PM | 1 |
| Lauritsen, H | 1 |
| Petersen, HH | 1 |
| Wehr, M | 1 |
| Lathrop, DA | 1 |
| Krapf, R | 1 |
| Gertsch, M | 1 |
| Teo, KK | 1 |
| Harte, M | 1 |
| Horgan, JH | 1 |
| Feld, G | 1 |
| Hendrickson, J | 1 |
| Singh, PN | 1 |
| Bennett, JM | 1 |
| Gourassas, J | 1 |
| Konstantinides, S | 1 |
| Kuhl, AJ | 1 |
| Prakash, R | 1 |
| Parmley, WW | 1 |
| Allen, HN | 1 |
| Matloff, JM | 1 |
| Khan, MI | 2 |
| Hamilton, JT | 2 |
| Manning, GW | 2 |
| Alter, WA | 1 |
| Weiss, GK | 1 |
| Priola, DV | 1 |
| Besterman, E | 1 |
| McCarthy, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
11 reviews available for sotalol and Tachyarrhythmia
| Article | Year |
|---|---|
Arrhythmias in Pregnancy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Pregnancy; Sotalol; Tachyca | 2022 |
Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.
Topics: Anti-Arrhythmia Agents; Digoxin; Female; Fetal Diseases; Fetal Therapies; Flecainide; Humans; Pregna | 2017 |
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Humans; Hy | 2003 |
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
[Long-term drug therapy of reciprocating supraventricular tachycardia: re-examination of a selected series of cases, using computerized programs].
Topics: Acebutolol; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents | 1980 |
[Sotalol].
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Humans; Metabolic Clear | 1995 |
Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Humans; Randomized Controlled Trial | 1997 |
Cardiac surgery: postoperative arrhythmias.
Topics: Algorithms; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiac Surgic | 2000 |
Drug treatment of fetal tachycardias.
Topics: Anti-Arrhythmia Agents; Clinical Trials as Topic; Digoxin; Female; Fetal Distress; Humans; Pregnancy | 2002 |
How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Evaluation; Electric Stimulation; Electrocardiography, Ambu | 1992 |
[New anti-arrhythmia agents].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardio | 1992 |
17 trials available for sotalol and Tachyarrhythmia
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bradycardia; Cardiac Pacing, Artificial; Fem | 2008 |
Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Coronary Artery | 2004 |
Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Drug Therapy, Combination; Elect | 2004 |
Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Dose-Response Relationship, Drug; Female; | 1981 |
Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).
Topics: Acute Disease; Adult; Aged; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Female; Heart R | 1995 |
Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Cardiac Output, Low; E | 1995 |
Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Chemotherapy, Adjuvant; Defibrilla | 1999 |
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Disopyramid | 1990 |
Efficacy of oral sotalol in reentrant ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Mid | 1990 |
Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambulatory; Electrophysiolo | 1990 |
Effects of intravenous sotalol, aprindine and the combination of sotalol and aprindine on chronic high frequency ventricular arrhythmias in man.
Topics: Aged; Aged, 80 and over; Aprindine; Cardiac Complexes, Premature; Clinical Trials as Topic; Drug The | 1987 |
Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: a randomized open trial.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Coronary Artery Bypass; Humans; Metoprolol; R | 1986 |
Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Tria | 1988 |
Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
Topics: Administration, Oral; Aged; Cardiac Pacing, Artificial; Clinical Trials as Topic; Coronary Disease; | 1988 |
The catecholamine response to acute myocardial infarction: effect of early administration of sotalol.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Epineph | 1986 |
Letter: Duration of action of beta-adrenergic blocking drugs.
Topics: Alprenolol; Animals; Clinical Trials as Topic; Heart Rate; Humans; Placebos; Sotalol; Tachycardia; T | 1974 |
93 other studies available for sotalol and Tachyarrhythmia
| Article | Year |
|---|---|
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Imidazoles; In Vitro Techniques; Purkinje | 1987 |
How to differentiate second-degree atrioventricular block from extrasystoles in fetuses with a bigeminal ventricular rhythm.
Topics: Atrioventricular Block; Cardiac Complexes, Premature; Digoxin; Female; Fetus; Flecainide; Humans; Pr | 2020 |
A case of palpitation and pre-syncope.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Sotalol; Sy | 2017 |
Intravenous sotalol use in a complex critically ill child: balancing the systems in choosing antiarrhythmic medication.
Topics: Administration, Intravenous; Adolescent; Anti-Arrhythmia Agents; Bone Marrow Transplantation; Echoca | 2017 |
Combined flecainide and sotalol therapy for multifocal atrial tachycardia in cardio-facio-cutaneous syndrome.
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Ectodermal Dysplasia; Electrocardiography; Facies | 2018 |
Case 1: Wheezing Unresponsive to Bronchodilators in a 4-month-old Boy.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Bronchiolitis; Bronchodilator Agents; Diagnosis, Differentia | 2015 |
Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Heart Ventricles; Heart-Assist Devices; Humans; Male; Midd | 2015 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
Treatment of fetal tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Electrophysiology; Digoxin; Female; Fetal Diseases; Huma | 2008 |
[Sotalol prevents atrio-ventricular tachycardia but not atrial fibrillation with rapid ventricular response in a patient wiht WPW syndrome].
Topics: Adult; Anti-Arrhythmia Agents; Catheter Ablation; Electrocardiography; Humans; Male; Marfan Syndrome | 2008 |
Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriur | 2008 |
First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Female; Humans; Male; Recurrence; R | 2010 |
Wide QRS Tachycardia in a young patient.
Topics: Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Blood Pressure; Defibrillators, | 2012 |
Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics.
Topics: Amniotic Fluid; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Female; Fetal Blood; Fetal | 2003 |
Tachycardia-induced elevations in cardiac troponin in the absence of coronary artery disease.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Catheter Abla | 2006 |
Sotalol in the treatment of fetal tachyarrhythmia.
Topics: Anti-Arrhythmia Agents; Fetal Diseases; Humans; Retrospective Studies; Sotalol; Tachycardia | 2006 |
[Suicide attempt with sotalol: a proarrhythmic intoxication].
Topics: Heart Arrest; Heart Rate; Humans; Male; Middle Aged; Pacemaker, Artificial; Sotalol; Suicide, Attemp | 2007 |
Prolongation of Q-Tc or Q-Uc interval and sotalol.
Topics: Electrocardiography; Heart; Humans; Sotalol; Tachycardia | 1981 |
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias.
Topics: Adrenergic beta-Antagonists; Atenolol; Electrocardiography; Heart Ventricles; Humans; Kinetics; Male | 1981 |
Sotalol, hypokalaemia, syncope, and torsade de pointes.
Topics: Adult; Aged; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography; Female; H | 1984 |
Sotalol, hypokalaemia, syncope, and torsade de pointes.
Topics: Aged; Humans; Hypokalemia; Sotalol; Syncope; Tachycardia | 1984 |
Sotalol induced torsade de pointes.
Topics: Electrocardiography; Humans; Isoproterenol; Male; Middle Aged; Sotalol; Tachycardia; Time Factors | 1984 |
Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase.
Topics: Action Potentials; Animals; Consciousness; Dogs; Electrocardiography; Heart Conduction System; Metop | 1983 |
Torsade de pointes.
Topics: Adult; Female; Humans; Sotalol; Tachycardia | 1983 |
Sotalol-induced torsade de pointes.
Topics: Adult; Electrocardiography; Female; Humans; Sotalol; Syncope; Tachycardia | 1984 |
Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; | 1984 |
Sotalol-induced torsade de pointes.
Topics: Aged; Electrocardiography; Female; Humans; Sotalol; Tachycardia | 1984 |
Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes).
Topics: Adult; Female; Heart Rate; Humans; Lidocaine; Male; Middle Aged; Pacemaker, Artificial; Sotalol; Sui | 1982 |
[Atrioventricular block and torsade de pointes following sotalol overdose].
Topics: Electrocardiography; Heart Block; Humans; Male; Middle Aged; Sotalol; Tachycardia | 1982 |
Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Electrocardiography; Female; Hemodynamics; Humans; Male; Mi | 1981 |
Satalol-induced torsade de pointes.
Topics: Adult; Humans; Kidney Failure, Chronic; Male; Sotalol; Tachycardia | 1981 |
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
Topics: Adult; Delayed-Action Preparations; Female; Half-Life; Heart Rate; Humans; Male; Oxprenolol; Physica | 1980 |
Rapid intravenous infusion of d-1 sotalol: time to onset of effects on ventricular refractoriness, and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Cardiac Pacing, Artificial; Electrocardi | 1995 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
Does sotalol have reverse-use dependence during tachyarrhythmias?
Topics: Aged; Anti-Arrhythmia Agents; Female; Heart Conduction System; Hemodynamics; Humans; Male; Middle Ag | 1996 |
Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1997 |
Sotalol for atrial tachycardias after surgery for congenital heart disease.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bradycardi | 1997 |
Acute pulmonary toxicity in an infant from intravenous amiodarone.
Topics: Acute Disease; Amiodarone; Bronchoalveolar Lavage Fluid; Dobutamine; Humans; Infant; Infant, Newborn | 1997 |
Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Electrocardiography; Guinea Pigs; Heart; | 1998 |
Redefining the role of antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Chemotherapy, Adjuvant; Defibrillators, Implantable; El | 1999 |
[Bioavailability of sotalol in short bowel syndrome].
Topics: Aged; Anti-Arrhythmia Agents; Biological Availability; Dose-Response Relationship, Drug; Female; Hum | 1999 |
[Ion channels and arrhythmias].
Topics: Action Potentials; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrial Fib | 2000 |
Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzamides; Cisapride; Dimethyl Sulfoxide; Disea | 2002 |
Toxicity of aerosol propellants in the respiratory and circulatory systems. VII. Influence of pulmonary emphysema and anesthesia in the rat.
Topics: Adrenergic beta-Antagonists; Aerosol Propellants; Aerosols; Anesthesia; Animals; Arrhythmias, Cardia | 1975 |
Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias.
Topics: Adult; Electrocardiography; Humans; Male; Middle Aged; Sotalol; Tachycardia | 1979 |
Electrophysiologic and antiarrhythmic effects of D-sotalol.
Topics: Action Potentials; Aged; Animals; Dogs; Electrophysiology; Female; Heart; Humans; Male; Middle Aged; | 1992 |
[Combination anti-arrhythmic drug therapy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Drug Therapy, Combination; Electro | 1992 |
d-Sotalol has opposite effects from encainide and propafenone on the proportion of episodes of ventricular tachycardia that are sustained in an experimental substrate for reentry.
Topics: Animals; Encainide; Heart Conduction System; Heart Rate; In Vitro Techniques; Male; Propafenone; Rab | 1992 |
Effectiveness of oral sotalol for treatment of pediatric arrhythmias.
Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Female; Heart Defects, Congenital; | 1992 |
Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk.
Topics: Adult; Cardiac Complexes, Premature; Drug Therapy, Combination; Female; Flecainide; Humans; Maternal | 1990 |
Reentrant tachycardia in a thin layer of ventricular subepicardium: effects of d-sotalol and lidocaine.
Topics: Action Potentials; Animals; Electric Stimulation; Electrophysiology; Freezing; Heart Ventricles; In | 1990 |
Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Artery Disease; Electrocardi | 1992 |
Life threatening 'epilepsy'.
Topics: Child, Preschool; Diagnosis, Differential; Epilepsy; Female; Humans; Sotalol; Tachycardia; Unconscio | 1991 |
Arrhythmogenic effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Prop | 1990 |
Sotalol in patients with life-threatening ventricular tachyarrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Angiography; Coronary Disease; Electric Stimulation; E | 1990 |
Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
Topics: Cardiac Pacing, Artificial; Female; Heart Ventricles; Humans; Male; Middle Aged; Recurrence; Sotalol | 1990 |
[Predictive value of programmed electrostimulation in patients with spontaneous idiopathic ventricular tachycardia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Ex | 1990 |
Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
Topics: Adult; Aged; Cardiac Complexes, Premature; Electrocardiography; Female; Heart Arrest; Heart Rate; Hu | 1988 |
Right ventricular tachycardia with left bundle branch block and inferior axis morphology: clinical and arrhythmological characteristics in 15 patients.
Topics: Adult; Angiocardiography; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Pacing, Artificial; E | 1989 |
Inadvertent catheter-induced right bundle branch block in a patient with preexistent left bundle branch block and recurrent macroreentrant ventricular tachycardia.
Topics: Aged; Amiodarone; Bundle-Branch Block; Cardiac Catheterization; Electric Stimulation; Electrocardiog | 1989 |
A comparison of sotalol and procainamide in symptomatic ventricular tachycardia.
Topics: Aged; Electric Stimulation; Electrophysiology; Heart Ventricles; Humans; Middle Aged; Procainamide; | 1989 |
QT prolongation and arrhythmia suppression.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Deafness; Death, Sudden; Elect | 1985 |
Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Chronic Disease; Drug Evaluation; Ele | 1989 |
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Topics: Aged; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1989 |
Acute induction of sustained ventricular tachycardia: a new porcine model.
Topics: Animals; Disease Models, Animal; Electric Stimulation; Electrocardiography; Heart; Heart Ventricles; | 1989 |
[Proarrhythmic effect of ajmaline in idiopathic ventricular tachycardia].
Topics: Adult; Ajmaline; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Infusions, Intravenous; | 1989 |
[Sotalol-induced torsades de pointe in the conscious dog with atrioventricular block. Role of hypokalemia].
Topics: Animals; Dogs; Electrocardiography; Female; Heart Block; Hypokalemia; Male; Research Design; Sotalol | 1988 |
Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sotalol; Tachycardia; | 1988 |
[Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?].
Topics: Administration, Oral; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Dose-Response Relationship, | 1988 |
A normal response to programmed stimulation does not preclude the occurrence of life-threatening torsades de pointes with sotalol.
Topics: Humans; Sotalol; Tachycardia | 1988 |
Sotalol-induced torsades de pointes in a patient with pre-existent normal response to programmed ventricular stimulation.
Topics: Aged; Cardiac Pacing, Artificial; Electrocardiography; Female; Humans; Long QT Syndrome; Sotalol; Ta | 1987 |
[In utero treatment of fetal tachycardias with a digitalis-beta blocker combination. Apropos of 2 cases].
Topics: Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Fetal Diseases; Humans; Pregnancy; | 1987 |
Termination of refractory ventricular tachycardia by a combination of intravenous sotalol and overdrive ventricular pacing.
Topics: Cardiac Pacing, Artificial; Combined Modality Therapy; Humans; Male; Middle Aged; Sotalol; Tachycard | 1987 |
Clinical course, serum concentrations and elimination rate in a case of massive sotalol intoxication.
Topics: Adult; Bundle-Branch Block; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; L | 1987 |
The antiarrhythmic effects of d-sotalol.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardio | 1987 |
[Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography | 1987 |
Torsades de pointes induced by sotalol.
Topics: Diuretics; Humans; Potassium; Sotalol; Tachycardia | 1987 |
Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Female; Heart Rate; | 1986 |
[Sotalol, hypokalemia and torsade de pointes ventricular tachycardia].
Topics: Benzothiadiazines; Diuretics; Female; Furosemide; Humans; Hypokalemia; Middle Aged; Sodium Chloride | 1986 |
[QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
Topics: Adult; Aged; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Electrocardiography; Female; Heart | 1986 |
Electromechanical characterization of the effects of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands.
Topics: Action Potentials; Animals; Dogs; Female; Heart; Heart Conduction System; Male; Membrane Potentials; | 1985 |
Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations.
Topics: Aged; Electrocardiography; Female; Humans; Sotalol; Tachycardia | 1985 |
Torsade de pointes induced by sotalol.
Topics: Drug Therapy, Combination; Humans; Maprotiline; Sotalol; Tachycardia | 1985 |
Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; | 1985 |
Sotalol infusion in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; Middle | 1985 |
Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Topics: Adult; Aged; Electrocardiography; Electrophysiology; Female; Heart Block; Humans; Injections, Intrav | 1985 |
Torsade de pointes induced by sotalol and hypokalaemia.
Topics: Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypokalemia; Male; Middle | 1985 |
[Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia].
Topics: Adult; Atrioventricular Node; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Conduct | 1985 |
[Electrophysiologic effect of sotalol in supraventricular tachycardias].
Topics: Adolescent; Adult; Atrioventricular Node; Cardiac Pacing, Artificial; Electrocardiography; Female; H | 1985 |
Effect of Sotalol on clinical arrhythmias.
Topics: Administration, Oral; Aged; Amino Alcohols; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1972 |
Early arrhythmias following experimental coronary occlusion in conscious dogs and their modification by beta-adrenoceptor blocking drugs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Consciousn | 1973 |
Vagally induced tachycardia in atropinized dogs: effect of beta-adrenergic blockade.
Topics: Adrenergic beta-Antagonists; Animals; Atropine; Bretylium Compounds; Dogs; Dose-Response Relationshi | 1973 |
Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Animals; Coronary Disease; Disease Models | 1972 |